However, recent in vitro studies showed that NUCB2/NESF-1 knockdown with siRNA or shRNA in bladder cancer, glioblastoma, endometrial cancer, and thyroid cancer cell lines resulted in the inhibition of cell proliferation [19,22,25]. Here, NUCB2 is linked to urinary bladder cancer.